Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol. 2022 04 20; 40(12):1301-1311.

View in: PubMed

subject areas

Antibodies, Monoclonal
Carcinoma, Non-Small-Cell Lung
Chemoradiotherapy
Disease Progression
Humans
Lung Neoplasms

authors with profiles

Marina Chiara Garassino